- Home
- ULY vs PMCB Comparison
ULY vs PMCB Comparison
Compare ULY & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULY
- PMCB
- Stock Information
- Founded
- ULY 2013
- PMCB 1996
- Country
- ULY United States
- PMCB United States
- Employees
- ULY N/A
- PMCB N/A
- Industry
- ULY
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ULY
- PMCB Health Care
- Exchange
- ULY Nasdaq
- PMCB Nasdaq
- Market Cap
- ULY 5.8M
- PMCB 6.7M
- IPO Year
- ULY N/A
- PMCB N/A
- Fundamental
- Price
- ULY $3.45
- PMCB N/A
- Analyst Decision
- ULY Strong Buy
- PMCB
- Analyst Count
- ULY 2
- PMCB 0
- Target Price
- ULY $11.50
- PMCB N/A
- AVG Volume (30 Days)
- ULY 983.2K
- PMCB 118.1K
- Earning Date
- ULY 11-11-2025
- PMCB 09-15-2025
- Dividend Yield
- ULY N/A
- PMCB N/A
- EPS Growth
- ULY N/A
- PMCB N/A
- EPS
- ULY N/A
- PMCB 0.01
- Revenue
- ULY $131,235,000.00
- PMCB N/A
- Revenue This Year
- ULY N/A
- PMCB N/A
- Revenue Next Year
- ULY $20.23
- PMCB N/A
- P/E Ratio
- ULY N/A
- PMCB $160.47
- Revenue Growth
- ULY N/A
- PMCB N/A
- 52 Week Low
- ULY $2.75
- PMCB $0.80
- 52 Week High
- ULY $17.99
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- ULY 43.39
- PMCB N/A
- Support Level
- ULY $2.75
- PMCB N/A
- Resistance Level
- ULY $5.60
- PMCB N/A
- Average True Range (ATR)
- ULY 0.45
- PMCB 0.00
- MACD
- ULY 0.03
- PMCB 0.00
- Stochastic Oscillator
- ULY 23.50
- PMCB 0.00
About ULY Urgent.ly Inc.
Urgently Inc is a connected mobility assistance software platform, matching vehicle owners and operators with service professionals who deliver traditional roadside assistance, proactive maintenance and repair services. The traditional experience of a vehicle breakdown is often stressful and inconvenient, compounded by processes that lack transparency and to long wait times. Urgently offers an alternative to this traditional experience, leveraging its digitally native software platform to match supply and demand in its network and deliver exceptional mobility assistance experiences at scale.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.